pyrazines has been researched along with thromboplastin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| LaChance, RM; Nicholson, NS; Parlow, JJ; Salyers, AK; South, MS; Suleymanov, OD; Szalony, JA; Wood, RS | 1 |
| Case, BL; Clare, M; Dice, TA; Fenton, RL; Girard, TJ; Hayes, MJ; Jones, DE; Kurumbail, RG; Lachance, RM; Neumann, WL; Nicholson, NS; Parlow, JJ; South, MS; Stallings, WC; Stegeman, RA; Stevens, AM; Wood, RS | 1 |
| Nicholson, NS; Parlow, JJ; Salyers, AK; South, MS; Suleymanov, OD; Szalony, JA; Wood, RS | 1 |
| Cheng, CY; He, SL; He, XF; Jiang, HH; Lin, GQ; Sun, Y; Tian, XM; Wang, GF; Wen, ZB | 1 |
| Auwerda, JJ; Bertina, RM; de Maat, MP; Leebeek, FW; Osanto, S; Sonneveld, P; Yuana, Y | 1 |
| Chen, Z; Huo, JR; Yang, L; Zhu, HY | 1 |
| Chen, XY; Jin, J; Li, WP; Rao, SM; Yan, FZ; Yan, JS; Yang, Y; Zhao, J | 1 |
| Arai, R; Fujimoto, K; Isozumi, Y; Koyama, T | 1 |
1 trial(s) available for pyrazines and thromboplastin
| Article | Year |
|---|---|
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Cell-Derived Microparticles; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Thromboplastin; Venous Thrombosis; Vincristine | 2011 |
7 other study(ies) available for pyrazines and thromboplastin
| Article | Year |
|---|---|
Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model.
Topics: Aminobenzoates; Animals; Bleeding Time; Dose-Response Relationship, Drug; Factor VIIa; Factor Xa Inhibitors; Fibrinolytic Agents; Forearm; Hemodynamics; Macaca fascicularis; Male; Prothrombin Time; Pyrazines; Sodium Chloride; Thrombin; Thromboplastin; Thrombosis | 2003 |
Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
Topics: Antithrombin III; Binding Sites; Combinatorial Chemistry Techniques; Crystallography, X-Ray; Drug Design; Factor VIIa; Fibrinolytic Agents; Humans; Inhibitory Concentration 50; Models, Molecular; Pyrazines; Recombinant Proteins; Serine Proteinase Inhibitors; Structure-Activity Relationship; Thiazoles; Thrombin; Thromboplastin | 2003 |
Assessment of bleeding propensity in non-human primates by combination of selective tissue factor/VIIa inhibition and aspirin compared to warfarin and aspirin treatment.
Topics: Aminobenzoates; Animals; Anticoagulants; Aspirin; Bleeding Time; Dose-Response Relationship, Drug; Drug Combinations; Factor VIIa; Hemorrhage; Macaca fascicularis; Male; Platelet Aggregation Inhibitors; Prothrombin Time; Pyrazines; Thromboplastin; Warfarin; Whole Blood Coagulation Time | 2004 |
[Effects of tetramethylpyrazine on thrombin-induced tissue factor expression in vascular endothelial cells].
Topics: Animals; Cell Line; Dose-Response Relationship, Drug; Endothelial Cells; Gene Expression Regulation; Humans; Pyrazines; RNA, Messenger; Thrombin; Thromboplastin; Time Factors | 2009 |
Effect of ligustrazine on mice model of hepatic veno-occlusive disease induced by Gynura segetum.
Topics: Animals; Asteraceae; Bilirubin; Biomarkers; Blotting, Western; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Early Growth Response Protein 1; Female; Gene Expression Regulation; Hepatic Veno-Occlusive Disease; Liver; Mice; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Serum Albumin; Thromboplastin; Time Factors; Transaminases; Transcription Factor RelA | 2011 |
[Screening drugs for regulating tissue factor gene expression].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Gene Expression; Humans; Molecular Sequence Data; Promoter Regions, Genetic; Pyrazines; Thromboplastin; Transcription Factors; Transcriptional Activation; U937 Cells | 2011 |
Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.
Topics: Blood Coagulation; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Phosphatidylserines; Pyrazines; Thalidomide; Thromboplastin | 2013 |